Browsing by Author "Aytekin, Aydin"

Now showing 1 - 3 of 3

Factors Affecting Survival in Operated Esophageal Squamous Cell Carcinoma
(Springer, 2022) Akgul, Nida; Sakin, Abdullah; Sahin, Suleyman; Aldemir, Mehmet Naci; Aytekin, Aydin; Alay, Murat; Kotan, Mehmet Cetin
Purpose Esophageal squamous cell carcinoma (ESCC) is an extremely fatal and relatively rare gastrointestinal system malignancy. This study aimed to investigate the factors affecting survival in operated patients with ESCC. Materials and Methods We included 110 patients (38 [34.5%] male; 72 [65.5%] female) aged >= 18 (median age, 54 [26-77]) years who were operated without any signs of metastases and followed up at Van Yuzuncu Yil University Dursun Odabasi Medical Center between 2004 and 2019. Results Initially, 39 (35.5%) patients were clinical lymph node-positive and 71 (64.5%) patients were negative. Thirty-five (31.8%) patients underwent surgery after neoadjuvant chemoradiotherapy (nCRT), and 75 (%68.2) patients underwent direct surgery without nCRT. Five-year overall survival (OS) was 84.4% and 59.2% in patients who underwent surgery after nCRT and in those who underwent direct surgery, respectively. Median OS was significantly longer in patients who underwent surgery after nCRT (p = 0.003). There was a statistically significant difference in OS in patients who underwent surgery after nCRT depending on tumor response (p = 0.04). In multivariate analysis, advanced pathologic stage (p = 0.002) adversely affected survival, whereas nCRT administration (p = 0.031) positively affected OS. Conclusion We suggest that nCRT should be administrated before surgery, especially in locally advanced ESCCs. In addition, we believe that nCRT response can be used as a good parameter for survival. These results, however, should be supported by prospective studies.
Investigation of Colorectal Cancer Distribution in Mardin Province
(2020) Aytekin, Aydin
Colorectal cancers are the third most common tumors both in the world and in Turkey. Its frequency may vary according to geographical regions, environmental conditions and feeding habits. This study aimed to investigate the distribution of CRC patients admitted to Mardin State Hospital Medical Oncology Outpatient Clinic according to age, sex, diagnosis and stage. The records of patients admitted to Mardin State Hospital Medical Oncology Clinic between 2014-2018 were reviewed retrospectively. Patients over 18 years of age were included in the study. Gender, diagnosis and disease stages of the patients were recorded. A total of 1208 patients were examined. 160 colorectal cancer patients (13.2%) were detected. 74 (46.3%) of the patients were female and 86 (53.8%) were male. The male / female patient ratio was 1.16 / 1. While the median age of the whole group was 57 (19-93), the median age of the women was 57.78 (24-86) and the median age of the men was 56 (19-93). The ratio of colon cancer / rectal cancer in men was 54/32 (62.8 / 37.2%), whereas it was 44/30 (59.5 / 40.5%) in women. There was no difference in the age of the groups according to the diagnosis of colon and rectal cancer and gender (p = 0.37 and p = 0.59). There was no difference between the groups when the diagnoses and stages were compared by gender (p = 0.66 and p= 0.18). When the application stage was examined in all groups, the least application was in stage 1, and the most common application was in stage 4. 32 patients (20%) were over 70 years old and 19 (11.9%) were over 75 years old. The number of patients ≤49 years and 50-64 years were 51 (31.9%) and 64 (40%), respectively. This study includes the first CRC data of Mardin province. CRC patients in Mardin are diagnosed at a younger age and in an advanced stage. Since diagnosis and treatment methods are not sufficient in Mardin, patients are mostly diagnosed outside the province. Therefore, the number of patients is limited. Nevertheless, the statistics will be the first to guide future studies.
Prognostic Significance of Basal 18f-Fdg Pet/Ct Maximum Standardized Uptake Value in Patients With Metastatic Renal Cell Carcinoma Who Were Treated With Sunitinib
(Imprimatur Publications, 2020) Aytekin, Aydin; Aldemir, Mehmet Naci; Sakin, Abdullah; Telci, Ufuk; Esen, Ramazan
Purpose: To determine whether there is a relationship between maximum standardized uptake (SUVmax) value of basal 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) that was performed before sunitinib treatment and treatment related survival in patients with metastatic renal cell carcinoma (mRCC). Methods: The data of 36 patients (female/male: 1/1, median age 57.36 years, range 31-74) were retrospectively analyzed in whom sunitinib treatment was started due to mRCC between 2008 and 2019 and who underwent basal 18F-FDG PET/CT examination before this treatment. The median SUVmax value was 6.8. Progression-free survival (PFS) and overall survival (OS) rates of patients, who had SUVmax value >6.8 (group I) (50%, n=18) and <= than 6.8 (group II) (50%, n=18), were compared. Results: Both PFS and OS were significantly lower in the group with high SUVmax (SUVmax> 6.8, group I) before the sunitinib treatment than the group with low SUVmax (SUVmax <= 6.8, group II). When patients with SUVmax value> 6.8 (group I) (50%, n=18) and <= 6.8 (group II) (50%, n=18) were compared the median PFS of group I patients was 6.83 months (95%CI: 6.14-7.52), while the median PFS of group II patients was 11.24 months (95%CI: 8.4-14.06) (p=0.035). The median OS in group I and II was 12.91 months (95%CI: 10.17-15.65) and 54.54 months (95%CI: 8.51-100), respectively (p=0.042). Conclusion: In this study it was found that PFS and OS were low in patients with high SUVmax value in 18F-FDG PET/CT performed before sunitinib treatment. As a result, 18F-FDG PET/CT SUVmax values measured before sunitinib treatment can be used to predict survival in mRCC patients.